Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Corcept Therapeutics ( (CORT) ).
On April 30, 2026, Corcept Therapeutics reported first quarter 2026 revenue of $164.9 million, up from $157.2 million a year earlier, but posted a net loss of $31.8 million versus prior net income as operating expenses climbed to $214.5 million on launch spending for Lifyorli and growth investments in its Cushing’s syndrome franchise. The company ended March with $515.4 million in cash and investments, expects to return to profitability in the second quarter of 2026, and raised its full-year 2026 revenue guidance to $950–$1,050 million, signaling confidence in accelerating product uptake.
Operationally, the quarter marked a turning point as the FDA approved Lifyorli (relacorilant) in March 2026 for women with platinum-resistant ovarian cancer, and in April the drug, in combination with nab-paclitaxel, was added as a preferred regimen in NCCN Guidelines, supporting strong early adoption. Corcept highlighted broad late-stage and mid-stage programs for relacorilant across multiple cancers and hypercortisolism, miricorilant in MASH, and dazucorilant in ALS, positioning the company to diversify beyond its legacy Cushing’s syndrome revenue base and potentially reshape its long-term growth and competitive profile in endocrine and oncology markets.
The most recent analyst rating on (CORT) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
The score is driven primarily by strong underlying financial quality (high margins, growth, and minimal leverage) and supportive earnings-call outlook (higher 2026 guidance and meaningful clinical progress). These positives are tempered by mixed technicals (short-term rebound but still below longer-term trend) and a relatively expensive valuation, alongside regulatory and legal risks highlighted on the call.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company focused on discovering and developing medications that modulate the effects of the hormone cortisol to treat severe endocrinologic, oncologic, metabolic and neurologic disorders. Its marketed products include Korlym and an authorized generic for Cushing’s syndrome, and it is expanding into oncology with Lifyorli for platinum-resistant ovarian cancer.
Average Trading Volume: 1,654,658
Technical Sentiment Signal: Hold
Current Market Cap: $5B
For an in-depth examination of CORT stock, go to TipRanks’ Overview page.